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LETTERS TO THE EDITOR
Coronary Endothelial Dysfunction in the
Early Months After Heart Transplantation
We read with interest the report by Aptecar et al. (1) that early
after heart transplantation, coronary vasodilator effects of bradyki-
nin are preserved despite abnormal response to intracoronary
injection of acetylcholine. This absence of alterations to the
vasodilator action of bradykinin is neither a new nor an
unexpected finding. In cardiac transplant recipients with normal
angiography, this preservation of the coronary response to endoge-
nous vasodilator peptides has already been reported not only for
substance P (2), as mentioned by Aptecar et al. (1), but also for
bradykinin (3). In contrast to acetylcholine and serotonin, bradykinin
and substance P are potent endothelium-dependent vasodilators.
Their endothelial vasodilator effects are not counterbalanced by a
direct constriction mediated by the stimulation of smooth muscle
receptors.
As pointed out in our previous study (3) also performed in the
early months following transplantation, the hypersensitivity to the
vasoconstrictor effect of serotonin is not directly related to a
decrease in endothelium-derived nitric oxide (NO) availability.
Indeed, acute L-arginine supplementation in transplant recipients,
as compared to hyperlipidemic patients, did not modify the
hypersensitivity to serotonin (3).
Immune processes such as cytokines produced by activated
macrophages and T cells play a major role in these abnormal
responses, probably even in the absence of rejection episodes (4).
First, this inflammatory response may promote the release of
endothelin, an endothelium-derived contracting factor (EDCF)
able to potentiate the vasoconstriction to various amines (5) and
seems to play a major role in the development of the graft
vasculopathy (6,7). Second, cytokines may also activate the induc-
ible isoform of nitric oxide synthase (iNOS), promoting the release
of potent oxidants such as superoxide anion and peroxynitrite (8).
In line with this hypothesis, the coronary vasoconstriction to
acetylcholine was enhanced in patients with rejection episodes
cited in Aptecar et al. (1).
Hence, from available data, it is unlikely that the coronary
endothelial NO synthase pathway is impaired early after heart
transplantation. The abnormal responses to serotonin and acetyl-
choline are probably related to the presence of EDCF and/or
changes in smooth muscle receptors. Therefore, a direct action on
the endothelial NO synthase via an enhanced bradykinin availabil-
ity by long-term angiotensin-converting enzyme (ACE) inhibi-
tion, as suggested by Aptecar et al. (1), should not markedly
improve the endothelial function.
Furthermore, according to animal studies (9), NO formation is
already enhanced by activation of iNOS in the early months after
transplantation. This enhanced NO availability may explain the
elevated resting coronary blood flow observed in the transplant
recipients of Aptecar et al. (1), which is congruent with previous
studies (10).
Therefore, therapeutical approaches, aiming at counteracting
these abnormalities, with endothelin antagonists or/and antioxi-
dants, seem more appealing than with ACE inhibitors, which may
worsen cyclosporine-induced nephrotoxicity.
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Diurnal Rhythms and
Hemostatic Factors in Atrial Fibrillation
In a recent publication, Li-Saw-Hee et al. (1) measured plasma
concentrations of soluble p-selectin, von Willebrand factor, soluble
thrombomodulin and fibrinogen at 6-h intervals in patients with
atrial fibrillation and detected no variation in levels of these
hemostatic factors over a 24-h period. On the basis of these results,
it was concluded that atrial fibrillation was associated with a loss of
diurnal variation in these hemostatic factors, and that this could
contribute to the high risk of stroke and thromboembolic compli-
cations in this condition. However, we believe that there are a
number of issues related to the experimental design and data
interpretation of this study that cast doubt on the validity of these
conclusions.
First, measurement of hemostatic factors was performed at 6-h
intervals: 12 midnight, 6 AM, 12 noon, and 6 PM. While this may
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have identified the peak levels of von Willebrand factor, which
occur around midday (2), in normal subjects, fibrinogen has a
circadian rhythm with peak levels occurring between 9 and 10 AM
and the nadir occurring about 9 and 10 PM (3,4). The sampling
times chosen by Li-Saw-Hee et al. (1) are thus likely to have
missed the peak and nadir levels of fibrinogen, with a consequent
reduction in the power of the study to detect a diurnal difference.
Second, it is not clear whether there are diurnal variations in
soluble p-selectin and thrombomodulin in healthy subjects. Thus,
studies of soluble P-selectin have been inconclusive, with one study
of 12 subjects reporting a decrease in levels at 12 noon (5) but
another study of nine subjects finding an increase in levels at 8 to
9 AM (6). Furthermore, as far as we are aware, there is no published
data about the existence of diurnal variation in thrombomodulin
levels within normal subjects. As Li-Saw-Hee et al. (1) did not
look for circadian changes in these hemostatic factors in their
control group, therefore it seems somewhat premature to conclude
that there has been a “loss” of diurnal variation of soluble p-selectin
and thrombomodulin in patients with atrial fibrillation.
Finally, conclusions about the effects of atrial fibrillation (AF)
on the diurnal pattern of hemostatic factors may have been
confounded by heterogeneity in the clinical features of the patients
studied. Only 50% of patients in the diurnal study had lone AF,
with the remainder having conditions such as hypertension,
diabetes and atherosclerotic disease, all of which are associated
with changes in hemostatic factors independent of cardiac rhythm
(7,8). Furthermore, 15% of the patients were smokers, which is
recognized to have acute effects on both coagulation (9) and
platelet activation (10,11). Moreover, the mean age of the patients
with AF was 73 years and older age is known to be accompanied
by activation of coagulation (12).
Understanding the potential contribution of changes in coagu-
lation processes, platelet activation and endothelial function to the
risk of thromboembolism in patients with AF is clearly an
important area of research. However, elucidation of the mecha-
nisms underlying such changes and their relationship to thrombo-
embolic risk will require rigorous experimental design and also
separation of the effects of AF per se from the influence of other
known modulators of hemostatic factors.
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REPLY
Diurnal rhythms in certain hemostatic factors may contribute to
the clustering of various cardiovascular events at certain times of
the day. We have been unable to find any diurnal variation in the
hypercoagulable state associated with atrial fibrillation (AF), as
indicated by variations in levels of von Willebrand factor, fibrin-
ogen, soluble P-selectin and thrombomodulin, in patients with
chronic AF, that could contribute to the high risk of stroke and
thromboembolism associated with this arrhythmia (1). We are
grateful to Peverill and Smolich for bringing to our attention a
number of previous publications that they consider as having a
bearing on the interpretation of our data.
Peverill and Smolich cite the study by Porta et al. (2), who
reported differences in levels of von Willebrand factor (defined by
immunoelectrophoresis) taken at 13 time points in nine patients
with diabetes who were treated with insulin twice in a 12-h period.
These data were analyzed by paired t testing: we used the
considerably more stringent Freidman’s repeated-measures two-
way analysis of variance. Furthermore, von Willebrand factor levels
are positively associated with insulin (3,4); consequently, we did
not consider the data from Porta et al. (2) to be entirely comparable
with ours. Peverill and Smolich also cite the reports by Kanabrocki
et al. (5,6), which reported levels of fibrinogen taken at eight time
points in 11 men (mean age 55 years) who were heterogeneous for
cardiovascular disease (and its risk factors), and analyzed these data
with a complex procedure (that is unavailable to us) involving “the
fit of a cosine curve by the method of least squares.” Therefore,
these subjects differ from those in our study of carefully selected
patients with chronic AF.
Peverill and Smolich cite two papers reporting essential physi-
ological changes in a cohort of healthy young men, a group most
different to our patients with AF. For example, Jilma et al. (7)
obtained five blood samples from 12 men (mean age 25 years) and
found a diurnal variation in levels of soluble P-selectin. Similarly,
Kirk et al. (8) took seven blood samples from nine men (mean age
23 years) and also found a variation in levels of soluble P-selectin.
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